Merck: Keytruda meets goal in head and neck cancer study
(CercleFinance.com) - Merck said late on Tuesday that its cancer drug Keytruda met the main goal of a late-stage study, significantly improving survival in patients with head and neck cancer.
A Phase-3 trial investigating Merck's anti-PD-1 therapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) met a primary endpoint of overall survival as monotherapy in patients whose tumours expressed PD-L1, the group said.
The trial will continue with no changes to evaluate the drug as monotherapy and in combination with platinum chemotherapy, Merck said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
A Phase-3 trial investigating Merck's anti-PD-1 therapy for first-line treatment of recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) met a primary endpoint of overall survival as monotherapy in patients whose tumours expressed PD-L1, the group said.
The trial will continue with no changes to evaluate the drug as monotherapy and in combination with platinum chemotherapy, Merck said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.